Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626006 | 0.95 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1POLB | |
| SCHEMBL12621845 | 0.95 | L3MBTL1 (0.65) | L3MBTL1ALDH1A1POLBPKMHTT | |
| SCHEMBL12626029 | 0.86 | ALDH1A1 (0.60) | L3MBTL1ALDH1A1 | |
| SCHEMBL12621982 | 0.86 | ALDH1A1 (0.60) | L3MBTL1ALDH1A1 | |
| SCHEMBL22191895 | 0.84 | L3MBTL1 (0.75) | L3MBTL1ALDH1A1PKM | |
| SCHEMBL12624020 | 0.84 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1 | |
| SCHEMBL12656095 | 0.84 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1 | |
| SCHEMBL12621987 | 0.84 | KMT2A (0.64) | L3MBTL1ALDH1A1PKM | |
| SCHEMBL15380943 | 0.84 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1 | |
| SCHEMBL12621946 | 0.83 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022098700-A1 | INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 | CASSAVA SCIENCES, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS (US) | 2019-07-30 | — | — | US | disclosed |
| US-20100280057-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BURNS BARBIER LINDSAY | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363239-B2 | Method for inhibiting growth of cancer cells | FLNA, FLNB, FSCN1 | L3MBTL1 1041/4885ALDH1A1 3552/4885POLB 2667/4885 |
| US-20100280057-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | FLNA, OPRL1, FLNB | L3MBTL1 2361/4885ALDH1A1 1689/4885POLB 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.